Oncology Clinical Trials 2015

The recent breakthroughs in understanding the molecular biology of cancer have led to an unprecedented number of new targets in oncology drug development. There are more cancer drugs in the research pipeline than any other type of therapy, corresponding directly with the number of oncology clinical trials. Why do phase III clinical trials in oncology fail so often? One simple answer does not exist to this critically important question. Success of an oncology trial depends on many factors: scientific, organizational, biostatistical, regulatory, ethical and economical.  The second annual Oncology Clinical Trials is designed to provide a comprehensive coverage of many of these components as well as present case studies of successful clinical trials.